The Sixth Annual Kidney Health Initiative Stakeholders Meeting

By Paul T. Conway and Katherine R. Tuttle

khi may meeting.PNGThe Kidney Health Initiative (KHI), a public-private partnership between the American Society of Nephrology (ASN) and the U.S. Food and Drug Administration (FDA), advances its mission of facilitating innovation and patient safety in kidney disease through its collaborative partnerships with 90 organizations, working together in the largest collaborative body in the kidney community. To date, KHI has completed 15 projects and published 11 peer reviewed articles, many of which have included patient co-authors.

KHI is convening its Sixth Annual Stakeholders Meeting May 14-15, 2018 in Silver Spring, MD where more than 170 diverse representatives from industry, health care, patient, and non-profit organizations, foundations, and government come together to share ideas, discuss ongoing projects, collect feedback, and collaborate on new endeavors.

This year’s meeting was developed around the theme of “Patients at the Center.”

“The KHI Board selected this theme to both honor the KHI mission and to highlight the inherent necessity of patient involvement at all stages of innovation. Patient are, and must remain, a reminder to the nephrology community that our quest for new therapies for kidney diseases should be fueled by an equal sense of urgency that patients experience everyday of their lives.
 
  - Paul T. Conway

 

 

During this year’s meeting, each session will include one or more patients to present content and perspective on the session topic. Pamela Duquette, KHI Patient and Family Partnership Council (PFPC) member, will speak at the Opening Session and KHI PFPC Vice-Chair and Member Kevin Fowler and Roberta Wager, MSN, RN will moderate sessions during the meeting. Many other patients are speaking throughout the entire program, including Karin Hehenberger, MD, PhD, Vanessa Evans, MA, and Caleb Davy. Notably, this year KHI has broken a record on the number of patient advocates who have registered to attend.

Our keynote speakers this year will be Dr. Janet Woodcock, Director of the U.S. FDA Center for Drug Evaluation and Research, and Bruce Greenstein, Chief Technology Officer at the U.S. Department of Health and Human Services (HHS). Mr. Greenstein brings a unique perspective that he has shared publicly several times – his outlook on kidney issues is shaped by his own experiences as a caregiver to his mother when she underwent dialysis treatments.  These speakers will provide the FDA perspective on KHI and explain how HHS, in a formal collaboration with ASN, plans to accelerate innovation in kidney disease through KidneyX.

The meeting will include breakout session to discuss project ideas and proposals that were submitted by KHI members. KHI executes its mission-driven objectives through support of projects proposed by members across all areas of the kidney community. Project Submission Cycle X is open through June 1, 2018 and members can submit project ideas that impact KHI’s strategic priorities:

  • Advancement of Patient and Family Partnership and Funding of Kidney Diseases
  • Biomarker and Pathogenesis Understanding
  • Clinical Trial Endpoints and Design
  • Clinical Trial Infrastructure and Developing the Evidence Base
  • Closer Collaboration with the FDA and Other Government Agencies

During the current tenth project submission cycle, KHI has received the following four project proposals seeking endorsement from the KHI Board of Directors. These proposals reflect the original purpose of KHI and rich diversity of its membership and interests. They have enormous prospects to positively impact clinical outcomes through prevention, diagnosis, treatment, and informed by patient insights.

Members will have an opportunity to discuss these proposals and provide input to the proposers during the Stakeholders Meeting. Once the portal closes on June 1, the KHI Board of Directors will review the proposals, score them based on their feasibility, impact, and likelihood to meet the KHI Mission. Meritorious proposals will be officially endorsed this summer. Once endorsed by the Board, interested individuals can apply to serve on KHI project workgroups this fall.

“I am tremendously excited and energized by the impact of KHI projects to-date. Our progressive evolution of the KHI into a leader of patients-at-center for innovation will truly change lives for the better.

  - Katherine R. Tuttle

 


This year’s Stakeholder Meeting showcases KHI’s diverse membership where nephrologists work at the cutting edge to provide inspiration and hope for patients while simultaneously increasing optimism in the field.  Moving into its sixth year, KHI anticipates continuing to leverage its broad coalition across the kidney professional and patient communities to collaborate with the FDA to clarify the path to approval for new drugs, devices, and diagnostics to shape clinical research and innovation in nephrology.

KHI would like to acknowledge and thank all of the members of the 2018 KHI Planning Committee for their efforts in planning and organizing the Sixth Annual KHI Stakeholders Meeting and for their superb support to us as colleagues in our roles and duties as Co-Chairs :

Prabir Roy-Chaudhury, MD, PhD, FASN

Kevin Fowler, Vice-Chair, KHI PFPC

Richard Fissel, KHI PFPC

Larry Kessler, ScD

Reshma Kewalramani, MD, FASN

Kristen Miller, PharmD

Krisha Polu, MD

Marlon Pragnell, PHD

Linda Upchurch

Roberta Wager, MSN, RN, KHI PFPC

Category:
Subcategory:
Author:
Paul T. Conway and Katherine R. Tuttle
Body:

khi may meeting.PNGThe Kidney Health Initiative (KHI), a public-private partnership between the American Society of Nephrology (ASN) and the U.S. Food and Drug Administration (FDA), advances its mission of facilitating innovation and patient safety in kidney disease through its collaborative partnerships with 90 organizations, working together in the largest collaborative body in the kidney community. To date, KHI has completed 15 projects and published 11 peer reviewed articles, many of which have included patient co-authors.

KHI is convening its Sixth Annual Stakeholders Meeting May 14-15, 2018 in Silver Spring, MD where more than 170 diverse representatives from industry, health care, patient, and non-profit organizations, foundations, and government come together to share ideas, discuss ongoing projects, collect feedback, and collaborate on new endeavors.

This year’s meeting was developed around the theme of “Patients at the Center.”

“The KHI Board selected this theme to both honor the KHI mission and to highlight the inherent necessity of patient involvement at all stages of innovation. Patient are, and must remain, a reminder to the nephrology community that our quest for new therapies for kidney diseases should be fueled by an equal sense of urgency that patients experience everyday of their lives.
 
  - Paul T. Conway

 

 

During this year’s meeting, each session will include one or more patients to present content and perspective on the session topic. Pamela Duquette, KHI Patient and Family Partnership Council (PFPC) member, will speak at the Opening Session and KHI PFPC Vice-Chair and Member Kevin Fowler and Roberta Wager, MSN, RN will moderate sessions during the meeting. Many other patients are speaking throughout the entire program, including Karin Hehenberger, MD, PhD, Vanessa Evans, MA, and Caleb Davy. Notably, this year KHI has broken a record on the number of patient advocates who have registered to attend.

Our keynote speakers this year will be Dr. Janet Woodcock, Director of the U.S. FDA Center for Drug Evaluation and Research, and Bruce Greenstein, Chief Technology Officer at the U.S. Department of Health and Human Services (HHS). Mr. Greenstein brings a unique perspective that he has shared publicly several times – his outlook on kidney issues is shaped by his own experiences as a caregiver to his mother when she underwent dialysis treatments.  These speakers will provide the FDA perspective on KHI and explain how HHS, in a formal collaboration with ASN, plans to accelerate innovation in kidney disease through KidneyX.

The meeting will include breakout session to discuss project ideas and proposals that were submitted by KHI members. KHI executes its mission-driven objectives through support of projects proposed by members across all areas of the kidney community. Project Submission Cycle X is open through June 1, 2018 and members can submit project ideas that impact KHI’s strategic priorities:

  • Advancement of Patient and Family Partnership and Funding of Kidney Diseases
  • Biomarker and Pathogenesis Understanding
  • Clinical Trial Endpoints and Design
  • Clinical Trial Infrastructure and Developing the Evidence Base
  • Closer Collaboration with the FDA and Other Government Agencies

During the current tenth project submission cycle, KHI has received the following four project proposals seeking endorsement from the KHI Board of Directors. These proposals reflect the original purpose of KHI and rich diversity of its membership and interests. They have enormous prospects to positively impact clinical outcomes through prevention, diagnosis, treatment, and informed by patient insights.

Members will have an opportunity to discuss these proposals and provide input to the proposers during the Stakeholders Meeting. Once the portal closes on June 1, the KHI Board of Directors will review the proposals, score them based on their feasibility, impact, and likelihood to meet the KHI Mission. Meritorious proposals will be officially endorsed this summer. Once endorsed by the Board, interested individuals can apply to serve on KHI project workgroups this fall.

“I am tremendously excited and energized by the impact of KHI projects to-date. Our progressive evolution of the KHI into a leader of patients-at-center for innovation will truly change lives for the better.

  - Katherine R. Tuttle

 


This year’s Stakeholder Meeting showcases KHI’s diverse membership where nephrologists work at the cutting edge to provide inspiration and hope for patients while simultaneously increasing optimism in the field.  Moving into its sixth year, KHI anticipates continuing to leverage its broad coalition across the kidney professional and patient communities to collaborate with the FDA to clarify the path to approval for new drugs, devices, and diagnostics to shape clinical research and innovation in nephrology.

KHI would like to acknowledge and thank all of the members of the 2018 KHI Planning Committee for their efforts in planning and organizing the Sixth Annual KHI Stakeholders Meeting and for their superb support to us as colleagues in our roles and duties as Co-Chairs :

Prabir Roy-Chaudhury, MD, PhD, FASN

Kevin Fowler, Vice-Chair, KHI PFPC

Richard Fissel, KHI PFPC

Larry Kessler, ScD

Reshma Kewalramani, MD, FASN

Kristen Miller, PharmD

Krisha Polu, MD

Marlon Pragnell, PHD

Linda Upchurch

Roberta Wager, MSN, RN, KHI PFPC

Area(s) of Interest:
Date:
Friday, May 11, 2018